07:17 AM EST, 12/05/2024 (MT Newswires) -- Nkarta ( NKTX ) said Thursday it opened enrollment for the Ntrust-2 trial and received clearance to initiate an investigator-sponsored trial to evaluate its experimental therapy, NKX019, in patients with myasthenia gravis.

The company said Ntrust-2 is a study to assess NKX019 in patients with systemic sclerosis, idiopathic inflammatory myopathy, and ANCA-associated vasculitis.

The investigator-sponsored study would be led by researchers at the University of California, Irvine, and the University of Kansas Medical Center, the company said.

It added the trials will evaluate the therapy's safety and potential to induce long-term remission by eliminating pathogenic B cells.

Preliminary data from the studies are expected in 2025.